Genta holds out for another year as it raises $12.7M to advance oral taxane, tesetaxel
This article was originally published in Scrip
Executive Summary
Having finally ditched its investigational antisense therapy for melanoma, Genasense, in May, Genta (scripintelligence.com, 24 May 2011) is to raise $12.7 million as a convertible loan bearing 12% annual interest from institutional investors.